---
title: "Case study: Development of a cardiac hypertrophy iPSC-derived disease model"
description: In this case study, we describe how we developed an innovative high throughput drug efficacy screening application in a model of hypertrophic cardiomyopathy, utilizing human iPSC-derived cardiomyocytes.
---

[Resources ](https://www.ncardia.com/insights/resources)

# [Case study: Development of a cardiac hypertrophy iPSC-derived disease model](https://www.ncardia.com/insights/resources/case-study-development-of-a-cardiac-hypertrophy-ipsc-derived-disease-model)

 Written by [Georgios Kosmidis, PhD](https://www.ncardia.com/insights/resources/author/georgios-kosmidis-phd) | October 1, 2021

Cardiovascular disease is a foremost cause of mortality worldwide, with an estimated 17.3 million deaths per year. A major obstacle for efficient drug discovery and development is the absence of physiologically relevant and predictive cell-based assays.

Human induced pluripotent stem cells (iPSCs) hold great potential as disease models for cardiovascular diseases. Not only can they recapitulate physiological features of mature cardiomyocytes, they also retain a patient's genetic background and can be produced in the large quantities required for [high throughput screening platforms](https://www.ncardia.com/discovery-services/screening).

### In this case study, we describe how we developed an innovative high throughput drug efficacy screening application in a model of hypertrophic cardiomyopathy, utilizing human [iPSC-derived cardiomyocytes](https://www.ncardia.com/discovery-services/modeling/ncyte-cardiomyocytes).

[View full post](https://www.ncardia.com/insights/resources/case-study-development-of-a-cardiac-hypertrophy-ipsc-derived-disease-model)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Georgios Kosmidis, PhD"
  },
  "dateModified" : "2024-10-02T18:15:54.512Z",
  "datePublished" : "2021-10-01T04:00:00Z",
  "headline" : "Case study: Development of a cardiac hypertrophy iPSC-derived disease model",
  "image" : {
    "@type" : "ImageObject",
    "height" : 220,
    "url" : "https://www.ncardia.com/hubfs/Case%20study-%20Development%20of%20a%20cardiac%20hypertrophy%20iPSC-derived%20disease%20model.png",
    "width" : 350
  },
  "mainEntityOfPage" : "https://www.ncardia.com/insights/resources/case-study-development-of-a-cardiac-hypertrophy-ipsc-derived-disease-model",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Resources"
  }
}
```